This application is from a collaborative research team which proposes to develop, characterize, and validate mouse models of myeloid leukemia as a component of the National Cancer Institute's Mouse Models of Human Cancer Consortium. The applicant team consists of investigators located at the University of California, San Francisco, St. Jude Children's Research Hospital, the University of Chicago, and the University of Minnesota who are expert in various aspects of mouse model development including targeted mutagenesis, conditional gene expression, adoptive transfer into irradiated recipients, retroviral-mediated mutagenesis, cytogenetic and spectral karyotype analysis, fluorescence in situ hybridization, immunocytochemical staining, and preclinical evaluation of novel therapeutics. The proposed studies will focus on generating new mouse models that reproduce common genetic lesions found in human leukemias, and upon fully characterizing and exploiting both new and existing models. A second aspect of this proposal involves efforts to enhance the technologies that exist for engineering genetic alterations in mice for discovering mutations, and for performing phenotypic and chromosomal analysis of cancer cells. The applicant group will develop an Internet Website to distribute information to the scientific research community and anticipates collaborating to characterize and validate murine models developed by other groups. The applicant team is fully committed to sharing resources and data with other members of the MHCC to achieve the overall goal of developing better murine cancer models and in ultimately translating this research into better therapies for human patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA084221-02
Application #
6175269
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (O3))
Program Officer
Marks, Cheryl L
Project Start
1999-09-30
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
2
Fiscal Year
2000
Total Cost
$695,975
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Heltemes-Harris, L M; Larson, J D; Starr, T K et al. (2016) Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia. Oncogene 35:3454-64
Sachs, Zohar; Been, Raha A; DeCoursin, Krista J et al. (2016) Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. Haematologica 101:1190-1199
Wong, Jasmine C; Weinfurtner, Kelley M; Alzamora, Maria Del Pilar et al. (2015) Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife 4:
Dail, Monique; Wong, Jason; Lawrence, Jessica et al. (2014) Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 513:512-6
Diaz-Flores, Ernesto; Goldschmidt, Hana; Depeille, Philippe et al. (2013) PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 6:ra105
Tesio, Melania; Oser, Gabriela M; Baccelli, Irène et al. (2013) Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J Exp Med 210:2337-49
Keng, Vincent W; Sia, Daniela; Sarver, Aaron L et al. (2013) Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 57:120-30
Bergerson, Rachel J; Collier, Lara S; Sarver, Aaron L et al. (2012) An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood 119:4512-23
Lyubynska, Natalya; Gorman, Matthew F; Lauchle, Jennifer O et al. (2011) A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med 3:76ra27
Wiesner, Stephen M; Geurts, Jennifer L; Diers, Miechaleen D et al. (2011) Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. Am J Hematol 86:579-85

Showing the most recent 10 out of 56 publications